UB Paderborn / Katalog / Suche / in CDI

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

Journal of the American Academy of Dermatology, 2024-05, Vol.90 (5), p.986-993

2024

Link zum Volltext

Verfügbarkeit prüfen

Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry

PloS one, 2022-01, Vol.17 (1), p.e0262151-e0262151

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial

JAMA dermatology (Chicago, Ill.), 2023-06, Vol.159 (6), p.613

2023

Link zum Volltext

Verfügbarkeit prüfen

Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States

Journal of the American Academy of Dermatology, 2015-10, Vol.73 (4), p.585-593.e3

2015

Link zum Volltext

Verfügbarkeit prüfen

Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study

Dermatology and therapy, 2023-06, Vol.13 (6), p.1255-1264

2023

Link zum Volltext

Verfügbarkeit prüfen

31865 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% for treatment of chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB93-AB93

2022

Link zum Volltext

Verfügbarkeit prüfen

15908 Long-term efficacy and safety of brodalumab in patients with or without metabolic syndrome

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB163-AB163

2020

Link zum Volltext

Verfügbarkeit prüfen

42297 Insights into the eﬃcacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB57-AB57

2023

Link zum Volltext

Verfügbarkeit prüfen

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

The New England journal of medicine, 2016-12, Vol.375 (24), p.2335-2348

2016

Link zum Volltext

Verfügbarkeit prüfen

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

The New England journal of medicine, 2021-03, Vol.384 (12), p.1101-1112

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis

The New England journal of medicine, 2021-12, Vol.385 (24), p.2219-2229

2021

Link zum Volltext

Verfügbarkeit prüfen

43759 Insights Into Baseline Demographics and Disease Characteristics in Subjects With Notalgia Paresthetica

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB182-AB182

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis

The New England journal of medicine, 2021-02, Vol.384 (6), p.512-520

2021

Link zum Volltext

Verfügbarkeit prüfen

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.1348-1358

2020

Link zum Volltext

Verfügbarkeit prüfen

25995 5-year efficacy of tildrakizumab 100 and 200 mg by PASI 50/75/90/100 and PGA in reSURFACE 1

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB80-AB80

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

American journal of clinical dermatology, 2019-12, Vol.20 (6), p.863-871

2019

Link zum Volltext

Verfügbarkeit prüfen

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

The New England journal of medicine, 2023-03, Vol.388 (12), p.1080-1091

2023

Link zum Volltext

Verfügbarkeit prüfen

The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis

Journal of the American Academy of Dermatology, 2022-12, Vol.87 (6), p.1455-1458

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)

JAMA dermatology (Chicago, Ill.), 2023-02, Vol.159 (2), p.182

2023

Link zum Volltext

Verfügbarkeit prüfen

15904 Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB162-AB162

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Trial of Difelikefalin in Notalgia Paresthetica

The New England journal of medicine, 2023-02, Vol.388 (6), p.511-517

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts

American journal of clinical dermatology, 2021-11, Vol.22 (6), p.867-875

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis

Clinical and experimental dermatology, 2023-06, Vol.48 (6), p.623-630

2023

Link zum Volltext

Verfügbarkeit prüfen

The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study

Journal of drugs in dermatology, 2023-02, Vol.22 (2), p.139

2023

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial

Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States

Topical Isotretinoin (TMB-001) Treatment for 12 Weeks Did Not Result in Clinically Relevant Laboratory Abnormalities in Participants with Congenital Ichthyosis in the Phase 2b CONTROL Study

31865 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% for treatment of chronic plaque psoriasis

15908 Long-term efficacy and safety of brodalumab in patients with or without metabolic syndrome

42297 Insights into the eﬃcacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis

43759 Insights Into Baseline Demographics and Disease Characteristics in Subjects With Notalgia Paresthetica

Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

25995 5-year efficacy of tildrakizumab 100 and 200 mg by PASI 50/75/90/100 and PGA in reSURFACE 1

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)

15904 Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1

Phase 2 Trial of Difelikefalin in Notalgia Paresthetica

Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts

Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis

The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study

Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials

Suchergebnisse filtern